Alpha Cognition (ACOG) closed at $8.62 on November 11, 2026, down 1.3% from the previous close, on volume of 114,894 shares (30-day average 101,110).
Data as of November 11, 2026.
Alpha Cognition GAAP EPS of -$0.35 misses by $0.02, revenue of $7.77M beats by $0.84M
Seeking Alpha News (Wed, 11-Nov 4:10 PM ET)
Alpha Cognition Inc. Reports Third Quarter 2026 Financial Results and Provides Operational Update
Business Wire (Wed, 11-Nov 4:05 PM ET)
Alpha Cognition Strengthens Its Board of Directors with Appointment of Caren Deardorf
Business Wire (Mon, 9-Nov 8:30 AM ET)
Alpha Cognition to Participate in Upcoming Investor Events
Business Wire (Fri, 6-Nov 3:00 PM ET)
Alpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business Update
Business Wire (Mon, 2-Nov 4:05 PM ET)
Business Wire (Tue, 13-Oct 8:30 AM ET)
Business Wire (Tue, 6-Oct 8:30 AM ET)
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 2-Oct 7:06 PM ET)
Business Wire (Thu, 1-Oct 8:30 AM ET)
Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update
Business Wire (Thu, 13-Aug 4:05 PM ET)
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Alpha Cognition trades on the NASDAQ stock market under the symbol ACOG.
As of November 11, 2026, ACOG stock price declined to $8.62 with 114,894 million shares trading.
ACOG has a beta of 2.55, meaning it tends to be more sensitive to market movements. ACOG has a correlation of 0.25 to the broad based SPY ETF.
ACOG has a market cap of $187.69 million. This is considered a Micro Cap stock.
Last quarter Alpha Cognition reported $6 million in Revenue and -$.40 earnings per share. This beat revenue expectation by $341,728 and missed earnings estimates by -$.01.
The top ETF exchange traded funds that ACOG belongs to (by Net Assets): AVSC.
ACOG has outperformed the market in the last year with a return of +37.7%, while the SPY ETF gained +12.6%. However, in the most recent history, ACOG shares have underperformed the stock market with its stock returning -3.0% in the last 3 month period and -3.3% for the last 2 week period, while SPY has returned -1.5% and -1.3%, respectively.
ACOG support price is $8.33 and resistance is $9.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACOG shares will trade within this expected range on the day.